gemcitabine + cisplatin + fluorouracil

Gemcitabine + cisplatin + fluorouracil is a combination chemotherapy regimen investigated by the Barbara Ann Karmanos Cancer Institute for the treatment of advanced pancreatic, gallbladder, and biliary tract cancers. The regimen consists of three established cytotoxic agents: gemcitabine, a nucleoside analog that inhibits DNA synthesis; cisplatin, a platinum-based agent that causes DNA cross-linking; and 5-fluorouracil (5-FU), an antimetabolite that inhibits thymidylate synthase. In clinical trials, this triplet combination was administered intravenously to patients with unresectable stage III or IV disease to evaluate its efficacy in stopping tumor cell division and improving survival outcomes. The regimen typically involves periodic intravenous administration of gemcitabine and cisplatin alongside a continuous infusion of 5-fluorouracil.

Other names

GCF regimenGem/Cis/5-FUGemcitabine-Cisplatin-5-FluorouracilGemcitabine-Cisplatin5-FluorouracilGemcitabine-Cisplatin 5-Fluorouracil